The risk of a biosimilar void in Europe by Giuliana Miglierini The undergoing revision of the pharmaceutical legislation aims, among others, to redefine data protection to…
What happens after IP loss of protection by Giuliana Miglierini What does it happen under a competitiveness perspective once intellectual property (IP) protection for medicinal…